MedPath

comparison of Clonidine and Dexmedetomidine for the duration of Post-operative Pain relief by Femoro-Sciatic Nerve Block in the patients of below knee Surgeries.

Completed
Conditions
healthy human volunteers
Registration Number
CTRI/2015/10/006328
Lead Sponsor
Dr RPGMC Kangra at Tanda
Brief Summary

to study the effect of adding adjuvent (clonidine and dexmedetomidine) to levo-bupivacaine in prolonging the post operative analgesia in below knee surgeries by femoro-sciatic nerve block.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Inclusion criteria – 1.Males and females between the age group 20-60 years.
  • 2.ASA class I-II.
  • 3.BMI 18.5-39.9. 4.Undergoing surgeries of leg and foot.
Exclusion Criteria
  • 1.Patient’s refusal for block.
  • 2.History of cardiac, renal or hepatic disease, CNS disorders, neuropathy.
  • 3.Chronic treatment with calcium channel blockers.
  • 4.Patients having bleeding disorders.
  • 5.Hypersensitivity to local anaesthetics.
  • 7.Knee surgery.
  • 8.Allergic to study drugs.
  • 9.Patients with known bradyarrythmia and on beta blocker therapy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome measure in this study is the time to first analgesic request.The primary outcome measure in this study is the time to first analgesic request.
Secondary Outcome Measures
NameTimeMethod
The secondary outcome measures include the number of supplemental analgesic requirements, VAS pain, nausea, patient satisfactionThe secondary outcome measures include the number of supplemental analgesic requirements, VAS pain, nausea, patient satisfaction

Trial Locations

Locations (1)

Dr. RPGMC Kangra at Tanda

🇮🇳

Kangra, HIMACHAL PRADESH, India

Dr. RPGMC Kangra at Tanda
🇮🇳Kangra, HIMACHAL PRADESH, India
Bhanu Gupta
Principal investigator
9418016807
bhanurpgmc@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.